Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT01248754 : Positron Emission Tomography (PET) With 3,4-dihydroxy-6-18F-fluoro-L-enylalanine (18F-FDOPA) Study
PhasePhase 2
AgesMin: 18 Years Max: N/A
Inclusion Criteria:

- Contrast-enhancing mass on diagnostic brain CT or MRI strongly suggesting a diagnosis
of WHO grade III or IV glioma

- Karnofsky Performance status (KPS) ? 70

- Age ?18 years

- Subject is able to understand and consent to study

- Glomerular filtration rate (GFR) ? 45 ml/minute

Exclusion Criteria:

- Indication for urgent craniotomy to relieve mass effect

- Only stereotactic biopsy indicated because tumour is located in eloquent brain.

- The enhancement on the T1 MRI sequence involves or abuts the basal ganglia

- Previous intracranial malignancy or any invasive malignancy unless free of disease >
5 years

- Prior cranial irradiation

- Contra-indications to systemic radiation exposure: pregnancy or breast feeding

- Subject exceeds the weight limit of the PET scanner bed (204.5 kg)

- Subjects taking medication such as Levodopa for the treatment of Parkinson's Disease

- Allergies or other contraindication to CT contrast or MRI contrast
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557